ARGX:NSD-argenx SE (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 330.68

Change

0.00 (0.00)%

Market Cap

USD 17.11B

Volume

0.18M

Average Target Price

USD 324.58 (-1.84%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands. Address: Willemstraat 5, Breda, Netherlands, 4811 AH

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

USD61.26B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD55.25B 20.66 14.64
REGN Regeneron Pharmaceuticals, Inc

N/A

USD48.27B 14.76 12.06
ALXN Alexion Pharmaceuticals, Inc

N/A

USD33.58B 56.16 33.22
BGNE BeiGene, Ltd

N/A

USD29.06B N/A N/A
RPRX Royalty Pharma plc

N/A

USD28.27B 22.60 14.17
SGEN Seagen Inc

N/A

USD27.38B 44.84 41.48
BNTX BioNTech SE

N/A

USD26.25B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD22.15B 26.59 3.17
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARGX

Symbol Name Weight Mer Price(Change) Market Cap
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

N/A

USD0.05B
EWK iShares MSCI Belgium ETF 0.00 % 0.51 %

N/A

USD0.04B
AADR AdvisorShares Dorsey Wrig.. 0.00 % 1.10 %

N/A

USD0.08B
DJMC:LSE iShares EURO STOXX Mid UC.. 0.00 % 0.40 %

N/A

USD0.42B
EXSD:F iShares STOXX Europe Mid .. 0.00 % 0.20 %

N/A

USD0.29B
IQQM:F iShares EURO STOXX Mid UC.. 0.00 % 0.40 %

N/A

USD0.42B
EXSD:XETRA iShares STOXX Europe Mid .. 0.00 % 0.20 %

N/A

USD0.44B
IQQM:XETRA iShares EURO STOXX Mid UC.. 0.00 % 0.40 %

N/A

USD0.42B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.44% 52% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.44% 52% F 59% F
Trailing 12 Months  
Capital Gain 133.89% 79% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 133.89% 79% C+ 85% B
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 80.83% 88% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 80.83% 88% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 102.06% 23% F 11% F
Risk Adjusted Return 79.20% 94% A 87% B+
Market Capitalization 17.11B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.60 30% F 21% F
Price / Cash Flow Ratio 127.17 2% F 4% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -23.21% 79% C+ 27% F
Return on Assets -13.50% 79% C+ 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.98 39% F 30% F
Short Percent N/A N/A N/A N/A N/A
Beta 0.83 76% C 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector